Poniard cancer drug misses goal in lung cancer


November 18, 2009

The Washington Post

SOUTH SAN FRANCISCO -- Poniard Pharmaceuticals Inc. said Monday its cancer drug candidate picoplatin did not help lung cancer patients live longer, sending its shares plunging in early trading.

Poniard was running a late-stage trial of picoplatin as a secondary treatment for non-small cell lung cancer, meaning the drug was given to patients who had previously been treated for the disease and had a relapse. But patients who received picoplatin did not live significantly longer than those who received the best supportive treatment, the company said... Read More